Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.36 USD | -1.75% | -0.40% | -9.91% |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The stock, which is currently worth 2024 to 0.29 times its sales, is clearly overvalued in comparison with peers.
- The company has a low valuation given the cash flows generated by its activity.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- With an expected P/E ratio at 248 and 20.5 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.91% | 1.33B | B+ | ||
-9.51% | 8.77B | B+ | ||
+1.83% | 1.47B | D | ||
-2.02% | 1.22B | - | ||
-26.95% | 766M | - | - | |
+3.73% | 459M | - | ||
+1.70% | 431M | - | - | |
-32.42% | 299M | - | - | |
-62.86% | 266M | - | ||
+0.92% | 218M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- OMI Stock
- Ratings Owens & Minor, Inc.